Author's response to reviews

Title: Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

Authors:

Jeetendra Eswaraka (jeetendra.eswaraka@pfizer.com)
Anand Giddabasappa (anand.giddabasappa@pfizer.com)
Guangzhou Han (guangzhou.han@pfizer.com)
Kush Lalwani (kush.lalwani@pfizer.com)
Koleen Eisele (Koleen.Eisele@pfizer.com)
Zheng Feng (Zheng.Feng@pfizer.com)
Timothy Affolter (Timothy.Affolter@pfizer.com)
James Christensen (James.Christensen@pfizer.com)
Gang Li (gang.li@pfizer.com)

Version: 2
Date: 14 July 2014

Author's response to reviews:

Dear Ms. Roselyn Remoto,

Re: MS: 2638009211355765

We have made the changes as per your request. Specifically, (1) all the page breaks have been taken out. (2) We have inserted line numbers for each page.

Hope these changes meets your requirement for review. Please let us know if you have any questions/concerns.

Thanks,

Anand